Synageva Biopharma (GEVA) Misses Q4 EPS, Revenue Views
Get Alerts GEVA Hot Sheet
Join SI Premium – FREE
Synageva Biopharma (NASDAQ: GEVA) reported Q4 EPS of ($0.65), $0.27 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $1.78 million.
For earnings history and earnings-related data on Synageva Biopharma (GEVA) click here.
For earnings history and earnings-related data on Synageva Biopharma (GEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Tops Q4 EPS by 18c, provides guidance
- Gold Royalty Corp. (GROY) Tops Q4 EPS by 2c ; Offers Guidance
- SK Hynix (000660:KS) PT Raised to KRW260 at JPMorgan, 'Rally likely to continue'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!